These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 26319226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K.
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Sella A, Hercbergs AH, Hanovich E, Kovel S.
    Chemotherapy; 2012 Sep; 58(3):200-5. PubMed ID: 22759787
    [Abstract] [Full Text] [Related]

  • 5. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
    Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R.
    Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
    [Abstract] [Full Text] [Related]

  • 6. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
    Fuertes Zamorano N, De Miguel Novoa MP, Molino González A, Díaz Pérez JÁ, Rojas-Marcos PM, Montañez Zorrilla MC.
    Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
    [Abstract] [Full Text] [Related]

  • 7. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.
    Pilanc KN, Elbüken F, Ordu Ç, Köksal G, Tekelioğlu MH, Okutur K, Göksel S, Köksal Ü, Akçal T, Tecimer C.
    Am J Ther; 2016 Dec; 23(2):e583-7. PubMed ID: 24901901
    [Abstract] [Full Text] [Related]

  • 8. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
    Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P.
    Br J Cancer; 2008 Aug 05; 99(3):448-54. PubMed ID: 18665181
    [Abstract] [Full Text] [Related]

  • 9. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC.
    Cancer; 2011 Feb 01; 117(3):534-44. PubMed ID: 20845482
    [Abstract] [Full Text] [Related]

  • 10. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM.
    J Natl Cancer Inst; 2007 Jan 03; 99(1):81-3. PubMed ID: 17202116
    [Abstract] [Full Text] [Related]

  • 11. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
    Grossmann M, Premaratne E, Desai J, Davis ID.
    Clin Endocrinol (Oxf); 2008 Oct 03; 69(4):669-72. PubMed ID: 18394019
    [Abstract] [Full Text] [Related]

  • 12. Hypothyroidism Presenting as Multiple Body Cavity Effusions.
    Kumar G, Kumar A, Bundela RP, Pokharna R, Ashdhir P, Nijhawan S.
    J Assoc Physicians India; 2016 Jul 03; 64(7):83-84. PubMed ID: 27759354
    [Abstract] [Full Text] [Related]

  • 13. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
    Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R.
    Urol Oncol; 2012 Sep 03; 30(5):704-10. PubMed ID: 20884255
    [Abstract] [Full Text] [Related]

  • 14. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ.
    J Clin Endocrinol Metab; 2011 Oct 03; 96(10):3087-94. PubMed ID: 21816788
    [Abstract] [Full Text] [Related]

  • 15. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
    Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y.
    Endocr J; 2010 Oct 03; 57(10):873-80. PubMed ID: 20733268
    [Abstract] [Full Text] [Related]

  • 16. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ.
    J Natl Cancer Inst; 2007 Jun 20; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract] [Full Text] [Related]

  • 17. Sunitinib induces hypothyroidism with a markedly reduced vascularity.
    Makita N, Miyakawa M, Fujita T, Iiri T.
    Thyroid; 2010 Mar 20; 20(3):323-6. PubMed ID: 20187785
    [Abstract] [Full Text] [Related]

  • 18. A case of Meigs' syndrome with preceding pericardial effusion in advance of pleural effusion.
    Okuda K, Noguchi S, Narumoto O, Ikemura M, Yamauchi Y, Tanaka G, Takai D, Fukayama M, Nagase T.
    BMC Pulm Med; 2016 May 10; 16(1):71. PubMed ID: 27160723
    [Abstract] [Full Text] [Related]

  • 19. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH, Hercbergs A, Davis PJ.
    J Natl Cancer Inst; 2007 Jun 20; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract] [Full Text] [Related]

  • 20. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
    Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S.
    Thyroid; 2015 Nov 20; 25(11):1255-61. PubMed ID: 26414109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.